Abstract
Gene expression is controlled by several epigenetic mechanisms involving post-translational modification of histones (acetylation, phosphorylation and others). These mechanisms in the brain are not only important for normal function but also for the development of pathologies when their derangement does occur. The present review deals with post-translational modifications of histones in two neurodegenerative diseases characterized by different etiology and pathological progression, Huntington’s disease and Parkinson’s disease. A relatively large body of evidence supports an important role of these mechanisms in Huntington’s disease while knowledge of similar mechanisms in Parkinson’s disease is at a lower degree of understanding. Starting from available information on pathologies, the present state of possible therapeutic targets is considered and future developments are discussed.
Keywords: Histone post-translational modifications, Huntinghton’s disease, Parkinson’s disease, HDACs inhibitors.
Current Pharmaceutical Design
Title:Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases
Volume: 19 Issue: 28
Author(s): Luis Emiliano Pena-Altamira, Elisabetta Polazzi and Barbara Monti
Affiliation:
Keywords: Histone post-translational modifications, Huntinghton’s disease, Parkinson’s disease, HDACs inhibitors.
Abstract: Gene expression is controlled by several epigenetic mechanisms involving post-translational modification of histones (acetylation, phosphorylation and others). These mechanisms in the brain are not only important for normal function but also for the development of pathologies when their derangement does occur. The present review deals with post-translational modifications of histones in two neurodegenerative diseases characterized by different etiology and pathological progression, Huntington’s disease and Parkinson’s disease. A relatively large body of evidence supports an important role of these mechanisms in Huntington’s disease while knowledge of similar mechanisms in Parkinson’s disease is at a lower degree of understanding. Starting from available information on pathologies, the present state of possible therapeutic targets is considered and future developments are discussed.
Export Options
About this article
Cite this article as:
Pena-Altamira Emiliano Luis, Polazzi Elisabetta and Monti Barbara, Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases, Current Pharmaceutical Design 2013; 19(28) . https://dx.doi.org/10.2174/13816128113199990355
DOI https://dx.doi.org/10.2174/13816128113199990355 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
p75NTR as a Therapeutic Target for Neuropsychiatric Diseases
Current Molecular Pharmacology From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?
Current Pharmaceutical Design Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Pharmacological Treatment of Diabetic Peripheral Neuropathy: An Update
CNS & Neurological Disorders - Drug Targets Pyridines and Imidazopyridines with Medicinal Significance
Current Topics in Medicinal Chemistry Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Involvement of microRNA-146a in the Inflammatory Response of S tatus Epilepticus Rats
CNS & Neurological Disorders - Drug Targets Relevance of Excitable Media Theory and Retinal Spreading Depression Experiments in Preclinical Pharmacological Research
Current Neuropharmacology Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Current Drug Safety Davunetide: Peptide Therapeutic in Neurological Disorders
Current Medicinal Chemistry The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Targeting the Cholinergic System for Neuroprotection and/or Enhancement of Functional Recovery Following Neurotrauma
Current Pharmaceutical Design Comparative Studies on Phospholipase A2 as a Marker for Gut Microbiota- liver-brain Axis in a rodent Model of Autism
Current Proteomics Editorial:Cannabis: Neurological Correlates in Abuse and Medical Use
CNS & Neurological Disorders - Drug Targets The Doublecortin Gene Family and Disorders of Neuronal Structure
Central Nervous System Agents in Medicinal Chemistry Memory-Enhancing Drugs: A Molecular Perspective
Mini-Reviews in Medicinal Chemistry Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Search for Molecular Basis of Antifungal Activity of Thiosemicarbazide Derivatives: A Combined in vitro Antifungal and Enzymatic Studies with in Silico Docking
Letters in Drug Design & Discovery Gabapentin and Pregabalin for the Acute Post-operative Pain Management. A Systematic-narrative Review of the Recent Clinical Evidences
Current Drug Targets